1887

Abstract

and are responsible for numerous nosocomial infections. The objective of this study was to determine the development of their susceptibility to ten antibiotics and the antibiotic consumption of patients with suspicion of urinary tract infection (UTI).

A retrospective study was conducted on the susceptibility profiles of and isolates from 749 urine samples gathered between January 2013 and December 2016, and on the consumption of imipenem, meropenem and piperacillin-tazobactam between 2014 and 2016.

Hospital patients were the source of 82 (91.1 %) of the 90 isolates detected and 555 (84.2 %) of the 659 isolates. Globally, the lowest percentage susceptibility values were found for fosfomycin, aztreonam and ciprofloxacin, while colistin continued to be the most active antibiotic . In 2016, the susceptibility of to carbapenem and piperacillin-tazobactam decreased to very low values, while the susceptibility of to carbapenem remained stable but its susceptibility to piperacillin-tazobactam decreased. There was a marked increase in the consumption of piperacillin-tazobactam.

In our setting, it is no longer possible to use carbapenems and piperacillin-tazobactam for empirical treatment of UTI due to or to use piperacillin-tazobactam for empirical treatment of UTI due to . Colistin was found to be the most active antibiotic . There was a marked increase in the consumption of piperacillin-tazobactam.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000742
2018-06-01
2024-12-11
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/6/790.html?itemId=/content/journal/jmm/10.1099/jmm.0.000742&mimeType=html&fmt=ahah

References

  1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148–165[PubMed]
    [Google Scholar]
  2. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health?. Int J Antimicrob Agents 2008; 32:106–119 [View Article][PubMed]
    [Google Scholar]
  3. Mishra SK, Rijal BP, Pokhrel BM. Emerging threat of multidrug resistant bugs–Acinetobacter calcoaceticus baumannii complex and methicillin resistant Staphylococcus aureus. BMC Res Notes 2013; 6:98 [View Article][PubMed]
    [Google Scholar]
  4. Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther 2008; 6:309–325 [View Article][PubMed]
    [Google Scholar]
  5. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538–582 [View Article][PubMed]
    [Google Scholar]
  6. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43:S49–S56 [View Article][PubMed]
    [Google Scholar]
  7. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46:1254–1263 [View Article][PubMed]
    [Google Scholar]
  8. Manchanda V, Singh NP. Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 2003; 51:415–418 [View Article][PubMed]
    [Google Scholar]
  9. Bernabeu-Wittel M, Pichardo C, García-Curiel A, Pachón-Ibáñez ME, Ibáñez-Martínez J et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319–325 [View Article][PubMed]
    [Google Scholar]
  10. Krcmery V, Kalavsky E. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2007; 13:943–944 [View Article][PubMed]
    [Google Scholar]
  11. Moffatt JH, Harper M, Adler B, Nation RL, Li J et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55:3022–3024 [View Article][PubMed]
    [Google Scholar]
  12. Sorlozano A, Jimenez-Pacheco A, de Dios Luna del Castillo J, Sampedro A, Martinez-Brocal A et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control 2014; 42:1033–1038 [View Article][PubMed]
    [Google Scholar]
  13. Ren G, Zhou M, Ding N, Zhou N, Li Q. Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. Exp Ther Med 2016; 12:1715–1718 [View Article][PubMed]
    [Google Scholar]
  14. Karuniawati A, Saharman YR, Lestari DC. Detection of carbapenemase encoding genes in Enterobacteriace, Pseudomonas aeruginosa, and Acinetobacter baumanii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. Acta Med Indones 2013; 45:101–106[PubMed]
    [Google Scholar]
  15. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010; 362:1804–1813 [View Article][PubMed]
    [Google Scholar]
  16. Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010; 10:CD007182
    [Google Scholar]
  17. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340:c2096 [View Article][PubMed]
    [Google Scholar]
  18. Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 2015; 12:570–584 [View Article][PubMed]
    [Google Scholar]
  19. Medina-Polo J, Sopeña-Sutil R, Benítez-Sala R, Lara-Isla A, Alonso-Isa M et al. Prospective study analyzing risk factors and characteristics of healthcare-associated infections in a Urology ward. Investig Clin Urol 2017; 58:61–69 [View Article][PubMed]
    [Google Scholar]
  20. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657–686 [View Article][PubMed]
    [Google Scholar]
  21. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14:742–750 [View Article][PubMed]
    [Google Scholar]
  22. Nwadike VU, Ojide CK, Kalu EI. Multidrug resistant acinetobacter infection and their antimicrobial susceptibility pattern in a nigerian tertiary hospital ICU. Afr J Infect Dis 2014; 8:14–18[PubMed]
    [Google Scholar]
  23. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y et al. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11:22–29 [View Article][PubMed]
    [Google Scholar]
  24. Sorlozano A, Gutiérrez-Fernández J. Performances from the laboratory to improve the clinical use of cefepime. Am J Infect Control 2015; 43:1022–1023 [View Article][PubMed]
    [Google Scholar]
  25. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant Gram-negative pathogens. Infect Chemother 2014; 46:149–164 [View Article][PubMed]
    [Google Scholar]
  26. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69:266–277 [View Article][PubMed]
    [Google Scholar]
  27. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; 49:526–535 [View Article][PubMed]
    [Google Scholar]
  28. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186:575–579 [View Article][PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.000742
Loading
/content/journal/jmm/10.1099/jmm.0.000742
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error